Cargando…

Management of metastatic renal cell carcinoma: The complexity of choice

Detalles Bibliográficos
Autores principales:	Brown, Jacqueline T., Bilen, Mehmet Asim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796511/ https://www.ncbi.nlm.nih.gov/pubmed/31501075 http://dx.doi.org/10.1016/j.ebiom.2019.08.049

Ejemplares similares

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
por: Rhoades Smith, Katherine Emilie, et al.
Publicado: (2019)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
por: Olsen, T. Anders, et al.
Publicado: (2021)

Editorial: Case reports in renal cell carcinoma
por: Zhuang, Tony Z., et al.
Publicado: (2023)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
por: Ivanyi, Philipp, et al.
Publicado: (2023)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2021)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma
por: Grünwald, Viktor, et al.
Publicado: (2020)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
por: Martini, Dylan J., et al.
Publicado: (2022)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Governing therapy choices: Power/Knowledge in the treatment of progressive renal failure
por: Holmes, Dave, et al.
Publicado: (2006)

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Renal recovery after acute kidney injury: choice of initial renal replacement therapy modality still matters
por: Schneider, Antoine G, et al.
Publicado: (2014)

Sedative Choice: The Chilling Confounder to Targeted Temperature Management
por: Hawkins, W. Anthony, et al.
Publicado: (2022)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices
por: Buka, Richard J., et al.
Publicado: (2022)

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review
por: Smith, Katherine Emilie Rhoades, et al.
Publicado: (2020)

Advancing the diagnosis and classification of renal cell carcinomas
por: Rothwell, Joseph A.
Publicado: (2021)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Management of metastatic renal cell carcinoma – mini review
por: Bharthuar, Anubha, et al.
Publicado: (2015)

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature
por: Ravindranathan, Deepak, et al.
Publicado: (2018)

The growing need for resources to help older adults manage their financial and healthcare choices
por: MacLeod, Stephanie, et al.
Publicado: (2017)

International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
por: Pagani, Olivia, et al.
Publicado: (2010)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Renal cell carcinoma and plasma cell myeloma: Coincidence or true association?
por: Mubarak, Muhammed
Publicado: (2014)

Renal Cell Carcinoma Metastatic to Thyroid Gland, Presenting Like Anaplastic Carcinoma of Thyroid
por: Riaz, Khalid, et al.
Publicado: (2013)

The Choices Facing Geriatrics
por: Patterson, Christopher, et al.
Publicado: (2012)

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma
por: Sekar, Rishi R., et al.
Publicado: (2017)

Reporting back environmental exposure data and free choice learning
por: Ramirez-Andreotta, Monica D., et al.
Publicado: (2016)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

Outcomes of Multi-disciplinary Management of Metastatic Renal Cell Carcinoma
por: Yan, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bf58pgdp1rv7r198a0jccicr3u